RK
Highly rated in
1
conditions

Dr. Ruth A. Karron

Baltimore, MD
Highly rated in
1
conditions
Specialties:Radiology
Age:66
Clinical Trials:Currently Recruiting for 2 Trials
Accepts:New Patients
Highly rated in
1
conditions
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Check Dr. Ruth A. Karron's experience treating your condition:
About Dr. Ruth A. Karron

Ruth Karron is a Radiologist in Baltimore, Maryland. Karron is highly rated in 1 condition, according to our data. Her top areas of expertise are Respiratory Syncytial Virus (RSV) Infection, Infantile Pneumothorax, and Collapsed Lung. She is licensed to treat patients in Maryland. Karron is currently accepting new patients.

Her clinical research consists of co-authoring 110 peer reviewed articles and participating in 22 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Ruth A. Karron it is best to call her office and ask if your insurance is accepted.

Dr. Ruth A. Karron accepts the following insurance:

  •  CareFirst
Locations
600 N Wolfe St, Baltimore, MD 21287
Background & Education
Specialties
Radiology
Licenses
Diagnostic Radiology in MD
Hospital Affiliations
Howard County General Hospital
Languages Spoken
English
Gender
Female
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

22 Clinical Trials
A Phase I Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine RSV ΔNS2 Δ1313 I1314L, Lot RSV#006A, Delivered as Nose Drops to RSV-Seropositive Children 12 to 59 Months of Age, RSV-Seronegative Infants and Children 6 to 24 Months of Age, and Infants 4 to 6 Months of Age
Enrollment Status: Recruiting
Publish Date: December 05, 2022
Intervention Type: Biological
Study Drug: RSV NS2/1313/I1314L Live-Attenuated Respiratory Syncytial Virus Vaccine
Study Phase: Phase 1
Phase Ib Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID/ΔM2-2/1030s, Lot RSV#010A, Delivered as Nose Drops to RSV-Seronegative Infants and Children 6 to 24 Months of Age
Enrollment Status: Recruiting
Publish Date: April 26, 2022
Intervention Type: Biological
Study Phase: Phase 1
Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-attenuated Respiratory Syncytial Virus Vaccine, RSV 6120/∆NS1, Lot RSV#018A, or RSV 6120/F1/G2/∆NS1, Lot RSV#016A, Delivered as Nose Drops to RSV-seropositive Children 12 to 59 Months of Age and RSV-seronegative Infants and Children 6 to 24 Months of Age
Enrollment Status: Active, not recruiting
Publish Date: February 09, 2022
Intervention Type: Biological
Study Drugs: RSV 6120/NS1 Live-Attenuated Respiratory Syncytial Virus VaccineRSV 6120/F1/G2/NS1 Live-Attenuated Respiratory Syncytial Virus Vaccine
Study Phase: Phase 1
Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, RSV 6120/∆NS2/1030s, Lot RSV#012A, Delivered as Nose Drops to RSV-Seropositive Children 12 to 59 Months of Age and RSV-Seronegative Infants and Children 6 to 24 Months of Age
Enrollment Status: Completed
Publish Date: January 20, 2022
Intervention Type: Biological
Study Drug: RSV 6120/NS2/1030s Live-Attenuated Respiratory Syncytial Virus Vaccine
Study Phase: Phase 1
Randomized Phase I Study of the Infectivity, Safety, and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Infants and Children 6 to 24 Months of Age
Enrollment Status: Unknown status
Publish Date: March 30, 2020
Intervention Type: Biological
Study Drugs: RSV NS2/1313/I1314L Live-Attenuated Respiratory Syncytial Virus VaccineRSV276
Study Phase: Phase 1
A Phase I Study of the Safety and Immunogenicity of a Single Dose of the Live Recombinant RSV D46cpΔM2-2 Vero Grown Virus Vaccine (Lot RSV #008A), Delivered as Nose Drops to RSV-Seropositive Children 12 to 59 Months of Age and RSV-Seronegative Infants and Children 6 to 24 Months of Age
Enrollment Status: Completed
Publish Date: March 30, 2020
Intervention Type: Biological
Study Phase: Phase 1
Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-attenuated Respiratory Syncytial Virus Vaccine, D46/NS2/N/ΔM2-2-HindIII, Lot RSV#011B, Delivered as Nose Drops to RSV-Seronegative Infants and Children 6 to 24 Months of Age
Enrollment Status: Completed
Publish Date: August 31, 2018
Intervention Type: Biological
Study Phase: Phase 1
Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-attenuated Respiratory Syncytial Virus Vaccine, LID cp ΔM2-2, Lot RSV#009B, Delivered as Nose Drops to RSV-Seronegative Infants and Children 6 to 24 Months of Age
Enrollment Status: Terminated
Publish Date: August 17, 2018
Intervention Type: Biological
Study Phase: Phase 1
Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-attenuated Respiratory Syncytial Virus Vaccine, LID ΔM2-2 1030s, Lot RSV#010A, Delivered as Nose Drops to RSV-Seronegative Infants and Children 6 to 24 Months of Age
Enrollment Status: Completed
Publish Date: February 13, 2018
Intervention Type: Biological
Study Phase: Phase 1
A Phase I Study of the Safety and Immunogenicity of the Recombinant Live-Attenuated Human Parainfluenza Type 2 Virus Vaccine, rHPIV2 15C/948L/Δ1724 Lot PIV2#109C, Delivered as Nose Drops to Adults 18 to 49 Years of Age, HPIV2-Seropositive Children 15 to 59 Months of Age, and HPIV2-Seronegative Infants and Children 6 to 59 Months of Age
Enrollment Status: Completed
Publish Date: April 04, 2017
Intervention Type: Biological, Other
Study Phase: Phase 1
A Phase I Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine RSV LID ΔM2-2, Lot RSV#007A, Delivered as Nose Drops to RSV-Seronegative Infants and Children 6 to 24 Months of Age
Enrollment Status: Completed
Publish Date: December 21, 2016
Intervention Type: Biological
Study Phase: Phase 1
A Phase I Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine RSV cps2, Lot RSV#005A, Delivered as Nose Drops to RSV-Seronegative Infants and Children 6 to 24 Months of Age
Enrollment Status: Completed
Publish Date: September 15, 2016
Intervention Type: Biological
Study Phase: Phase 1
A Phase I Study of the Safety and Immunogenicity of the Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, RSV MEDI ΔM2-2 Lot RSV#002A, Delivered as Nose Drops to Adults 18 to 49 Years of Age, RSV-Seropositive Children 12 to 59 Months of Age, and RSV-Seronegative Infants and Children 6 to 24 Months of Age
Enrollment Status: Completed
Publish Date: December 15, 2015
Intervention Type: Biological
Study Phase: Phase 1
A Phase I Study of the Safety and Immunogenicity of the Recombinant Live-Attenuated Human Metapneumovirus Vaccine, rHMPV-Pa Lot HMPV #101A, Delivered as Nose Drops to Adults 18 to 49 Years of Age, HMPV-Seropositive Children 12 to 59 Months of Age, and HMPV-Seronegative Infants and Children 6 to 59 Months of Age
Enrollment Status: Completed
Publish Date: December 15, 2015
Intervention Type: Biological
Study Phase: Phase 1
A Phase I Study of the Safety and Immunogenicity of the Recombinant Live-Attenuated Human Parainfluenza Type 1 Virus Vaccine, rHPIV1 84/del170/942A, Lot PIV1 #104A, Delivered as Nose Drops to Adults 18 to 49 Years of Age, HPIV1-Seropositive Children 15 to 59 Months of Age, and HPIV1-Seronegative Infants and Children 6 to 59 Months of Age
Enrollment Status: Completed
Publish Date: February 25, 2013
Intervention Type: Biological
Study Phase: Phase 1
Phase 1 Inpatient Study of rHMPV-SHs, a Human Metapneumovirus Challenge Strain, Administered to Healthy Adults in Isolation
Enrollment Status: Completed
Publish Date: January 03, 2013
Intervention Type: Biological
Study Phase: Phase 1
A Phase 1 Study of the Safety and Immunogenicity of the Recombinant Live-Attenuated Chimeric Bovine/Human Parainfluenza Type 3 Virus Vaccine, rB/HPIV3, Lot PIV3 #101A, Delivered as Nose Drops to Adults 18 to 49 Years of Age, HPIV3-Seropositive Children 15 to 59 Months of Age, and HPIV3-Seronegative Infants and Children 6 to 36 Months of Age
Enrollment Status: Completed
Publish Date: March 01, 2012
Intervention Type: Biological
Study Phase: Phase 1
Phase 1 Study to Determine the Safety, Infectivity, and Tolerability of Two Doses of Live Attenuated Recombinant Cold Passaged (cp) 45 Parainfluenza Type 3 Virus Vaccine, rHPIV3cp45, Lot PIV3 102A, Delivered as Nose Drops to Infants 6 to 12 Months of Age, and to HPIV3 Seronegative Infants and Children 6 to 36 Months of Age
Enrollment Status: Completed
Publish Date: July 16, 2010
Intervention Type: Biological
Study Phase: Phase 1
Phase I Inpatient Study of the Safety and Immunogenicity of H9N2 (6-2) AA ca Reassortant (A/Chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca), a Live Attenuated Virus Vaccine Candidate for Prevention of Avian Influenza H9N2 Infection in the Event of a Pandemic (Study A)
Enrollment Status: Completed
Publish Date: January 21, 2008
Intervention Type: Biological
Study Phase: Phase 1
Phase 1 Inpatient Study of the Safety and Immunogenicity of Live Influenza A Vaccine H5N1 (6-2) AA ca Recombinant (A/VietNam/1203/2004 x A/AnnArbor/6/60/ca), a Live Attenuated Virus Vaccine Candidate for the Prevention of Avian Influenza H5N1 Infection in the Event of a Pandemic
Enrollment Status: Completed
Publish Date: January 21, 2008
Intervention Type: Biological
Study Phase: Phase 1
Phase 1 Inpatient Study of the Safety and Immunogenicity of H9N2 (6-2) AA ca Reassortant (A/Chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca), a Live Attenuated Virus Vaccine Candidate for Prevention of Avian Influenza H9N2 Infection in the Event of a Pandemic (Study B)
Enrollment Status: Completed
Publish Date: January 21, 2008
Intervention Type: Biological
Study Phase: Phase 1
Phase I Inpatient Study of the Safety and Immunogenicity of Live Influenza A Vaccine Modified H5N1 (6-2) AA ca Recombinant (A/Hong Kong/213/2003 x A/AnnArbor/6/60 ca), a Live Attenuated Virus Vaccine Candidate for Prevention of Avian Influenza H5N1 Infection in the Event of a Pandemic
Enrollment Status: Completed
Publish Date: November 20, 2007
Intervention Type: Biological
Study Phase: Phase 1
View 20 Less Clinical Trials -
110 Total Publications
Lack of clear national policy guidance on COVID-19 vaccines influences behaviors in pregnant and lactating women in Kenya.
Journal: Human vaccines & immunotherapeutics
Published: October 31, 2022
Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
EF
Dr. Elliot K. Fishman
Radiology
Highly rated in
24
conditions
Radiology

Johns Hopkins Health System

The Johns Hopkins Hospital

1800 Orleans St, 
Baltimore, MD 
 0.1 mi

Elliot Fishman is a Radiologist in Baltimore, Maryland. Fishman has been practicing medicine for over 46 years and is highly rated in 24 conditions, according to our data. His top areas of expertise are Neuroendocrine Tumor, Pancreatic Ductal Adenocarcinoma, Pancreatic Adenoma, Endoscopy, and Small Bowel Resection. He is licensed to treat patients in Maryland. Fishman is currently accepting new patients.

DR
Dr. Daniel S. Reich
Neurology | Radiology | Neuroradiology
Highly rated in
10
conditions
Neurology
Radiology
Neuroradiology

600 N Wolfe St, 
Baltimore, MD 

Daniel Reich is a Neurologist and a Radiologist in Baltimore, Maryland. Reich is highly rated in 10 conditions, according to our data. His top areas of expertise are Multiple Sclerosis (MS), CACH Syndrome, Progressive Multifocal Leukoencephalopathy, and Stroke. He is licensed to treat patients in Maryland.

GJ
Dr. Gaurav Jindal
Radiology | Neuroradiology
Highly rated in
9
conditions
Radiology
Neuroradiology

University of Maryland Medical System

University Of Maryland Diagnostic Imaging Specialists, P A

22 S Greene St, 
Baltimore, MD 
 1.9 mi

Gaurav Jindal is a Radiologist and a Neuroradiologist in Baltimore, Maryland. Jindal has been practicing medicine for over 20 years and is highly rated in 9 conditions, according to our data. His top areas of expertise are Brain Aneurysm, Arteriovenous Malformation, Stroke, Stent Placement, and Transmyocardial Revascularization. He is licensed to treat patients in Maryland. Jindal is currently accepting new patients.